Hashimoto S, Koike T, Tatewaki W, Seki Y, Sato N, Azegami T, Tsukada N, Takahashi H, Kimura H, Ueno M
First Department of Internal Medicine, Niigata University School of Medicine, Japan.
Leukemia. 1994 Jul;8(7):1113-5.
In contrast to patients with disseminated intravascular coagulation (DIC) due to other causes, patients with acute promyelocytic leukemia (APL) receiving standard cytotoxic chemotherapy can be treated safely with antifibrinolytic drugs for prophylaxis of hemorrhage, without the occurrence of thromboembolic complications. However, such drugs should be used cautiously in APL patients who are receiving all-trans retinoic acid (ATRA) differentiation therapy. We report here a patient with APL who had fatal thromboembolism after receiving ATRA and tranexamic acid therapy.
与因其他原因导致弥散性血管内凝血（DIC）的患者不同，接受标准细胞毒性化疗的急性早幼粒细胞白血病（APL）患者可以安全地使用抗纤维蛋白溶解药物预防出血，而不会出现血栓栓塞并发症。然而，此类药物在接受全反式维甲酸（ATRA）分化治疗的APL患者中应谨慎使用。我们在此报告一名APL患者，其在接受ATRA和氨甲环酸治疗后发生了致命的血栓栓塞。
